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Inequalities in the patterns of dermoscopy use
and training across Europe: conclusions of the
Eurodermoscopy pan-European survey
Background: Dermoscopy is a widely used technique, recommended in
clinical practice guidelines worldwide for the early diagnosis of skin
cancers. Intra-European disparities are reported for early detection and
prognosis of skin cancers, however, no information exists about regional
variation in patterns of dermoscopy use across Europe. Objective: To
evaluate the regional differences in patterns of dermoscopy use and train-
ing among European dermatologists. Materials & Methods: An online
survey of European-registered dermatologists regarding dermoscopy
training, practice and attitudes was established. Answers from Eastern
(EE) versus Western European (WE) countries were compared and their
correlation with their respective countries’ gross domestic product/capita
(GDPc) and total and government health expenditure/capita (THEc and
GHEc) was analysed. Results: We received 4,049 responses from 14
WE countries and 3,431 from 18 EE countries. A higher proportion
of WE respondents reported dermoscopy use (98% vs. 77%, p<0.001)
and training during residency (43% vs. 32%) or anytime (96.5% vs.
87.6%) (p<0.001) compared to EE respondents. The main obstacles in
dermoscopy use were poor access to dermoscopy equipment in EE and



















correlated with rate of dermoscopy use and dermoscopy training during
residency (Spearman rho: 0.5-0.7, p<0.05), and inversely with avail-
ability of dermoscopy equipment. Conclusion: The rates and patterns of24
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dermoscopy use vary significantly between Western and Eastern Europe,
on a background of economic inequality. Regionally adapted interven-
tions to increase access to dermoscopy equipment and training might
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ermoscopy is a non-invasive skin imaging tech-
nique widely used in dermatological practice, with
a solid evidence-based benefit in improving the
arly diagnosis of skin cancers [1-5]. It is currently recom-
ended as an integrant part of diagnosis in most European
nd international guidelines for skin cancer management
6-9]. Across Europe, important disparities in the burden
nd outcomes of skin cancers [10-13], as well as in the
arly detection of these tumours [14-17], have been docu-
ented, with late detection and poor prognosis followingJD, vol. 30, n◦ 5, September-October 2020
north-south, west-east gradient. Therefore, conceivably,
ifferent patterns of use of dermoscopy between coun-
ries may be one of the many components accounting for
hese disparities, and one that could be amended through
ell-guided interventions. Based on this hypothesis, we
ave recently performed the first pan-European study on
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nd Methodius”, Skopje, Republic of North Macedoniapatterns of dermoscopy use by dermatologists. We pre-
viously reported on the first pooled results, highlighting
the main overall facilitators and obstacles for implement-
ing this technique in everyday practice at continental level
[18]. We also found that many dermatologists considered
that dermoscopy improved the sensitivity and specificity of
melanoma diagnosis [19]. In the present work, we deep-
ened the analysis to investigate potential differences in
the patterns, training, context, and attitudes towards der-
moscopy use between European regions and countries. As
a one-size-fits-all solution cannot solve the complex health-
care problems of a heterogeneous continent, we anticipate
that this study may guide future interventions adapted to
regional context, to increase the early detection of skin
cancers while reducing the costs of invasive diagnosis.
Materials and methods
The Eurodermoscopy pan-European survey was conducted
under the auspices of the International Dermoscopy Soci-
ety (IDS), and its methodology was described in detail
previously [18]. In brief, it consisted of an online survey
distributed between June to December 2014 to all licensed
dermatologists registered in 32 European countries, using a
20-item questionnaire that covered demographic, practice-
related and training characteristics, as well as patterns of
dermoscopy use and dermatologists’ attitudes and opinions
about dermoscopy. Translation in the national languages
and dissemination of the survey in each country was
coordinated by a National Coordinating Team. The IDS
web-based tool for online surveys was used to collect
online responses into an access-restricted central database,
grouped by country access code. Duplicate and incomplete
responses were excluded from analysis. The number of
dermatology specialists registered in each country as per
December 2014, was provided by each National Coordina-
tor, based on the official statistics of the relevant national
authority. The response rate was calculated as the num-
ber of responses received divided by the total number of
dermatologists registered in that country. High use of der-
moscopy was defined, as described previously [18], as use
of dermoscopy in at least 50% of all cases of pigmented
and non-pigmented tumours and inflammatory lesions.
Country grouping
The participating countries, as defined by the United
Nations Organization [20], were grouped as follows:
– Eastern Europe (EE): Belarus, Bulgaria, Croatia, Czech
Republic, Estonia, Hungary, Latvia, Lithuania, FYRO
Macedonia, Poland, Romania, Russia, Serbia, Slovakia,
Slovenia, Georgia, Israel, Turkey
– Western Europe (WE): Austria, Belgium, France, Ger-525
many, Greece, Ireland, Italy, the Netherlands, Norway,
Portugal, Spain, Sweden, Switzerland, The United King-
dom.
The grouping of the countries in the two regions was based
on their geographical position and classification of Euro-




































ealth Organization (WHO) [21], as well as taking into
ccount the reported similarities in skin cancer epidemi-
logy [10, 11, 22], structure of national health systems,
ocioeconomic background, and post-war political and his-
orical setting [12, 23]. The two regions had comparable
urvey response rates.
conomic context
ata on participating countries’ total population, Gross
omestic Product/capita (GDPc), Government Health
xpenditure/capita (GHEc) and Total Health Expen-
iture/capita (THEc) expressed in US dollars were
ollected for the year of the survey in 2014 from the
orld Health Organization Global Health Expenditure
atabase [24].
tatistical analysis
or statistical analysis, R software [25] was used. The chi-
quared test was used to compare proportions of two groups
nd the chi-squared test for trends in proportions was used
o compare proportions of ordered groups. Continuous data
re given as means and standard deviations unless stated
therwise, and parametric tests for comparing groups were
nly used if corresponding assumptions were met. Corre-
ations between two continuous variables were tested with
he Spearman’s rank correlation coefficient (unless stated
therwise) as most correlations showed a monotonous
ut not linear trend. A two-sided p value of <0.05 was
egarded as statistically significant, and for univariate anal-
ses values, was adjusted according to the method of
olm [26].26
esults
e received 4,049 responses from 14 countries in the WE
egion and 3,431 responses from 18 countries from the EE
egion. The response rates in the two regions were compa-
able 1. Demographic and practice-related characteristics of derm
Weste
(%, n
No. of respondents 4049
Female participants 59.97
Age (mean) 49.2 (
Place of work -




-Involved in teaching activity for dermatology residents 12.42
No. of years as dermatology specialist (mean) 17.35
No. of patients seen/month (mean) 449.7
No. of skin cancer patients seen/month (mean) 83.82
Dermoscopy training received during residency 43.51
Dermoscopy training received outside residency 96.49
No. of respondents who use dermoscopy 98.33rable, namely 20% of all dermatologists in WE and 23% of
all dermatologists in EE.
Demographics and rates of dermoscopy use
There were several statistically significant differences
(table 1) between the two European sub-regions. WE
respondents included a lower proportion of women, had
older median age, and reported more patients in general
and more cancer patients seen monthly. A higher proportion
of WE respondents reported dermoscopy training during
residency (43.51% vs 32%, p<0.001) or any form of der-
moscopy training (96.5% vs 86.18%). Almost half of WE
respondents were working in individual private practices
and 22% in public health facilities; the opposite was true
for EE respondents. In all, 3,950 dermatologists (98.33%)
in WE and 2,652 dermatologists (77.84%) in EE reported
using dermoscopy (table 1).
Patterns of dermoscopy use
Among the dermatologists reporting dermoscopy use, WE
respondents reported longer dermoscopy practice and more
intensive use of this technique across all types of skin
lesions than EE physicians (table 2).
Fifty-seven percent of WE and 41% of EE dermatolo-
gists reported using polarized dermoscopy devices. Video
dermoscopy systems were used by a third (30%) of der-
matologists in WE and 16% of dermatologists in EE. The
algorithms for melanoma diagnosis most frequently used
were pattern analysis in WE (35%) and the ABCD rule
in EE (43% of respondents). Thirty-one percent of der-
moscopy users in WE and 23% in EE did not regularly
use any algorithm.EJD, vol. 30, n◦ 5, September-October 2020
Dermoscopy increased self-reported melanoma recognition
for 90% of respondents in EE and 84% in WE. Fewer
respondents in EE (60%) than in WE (78%) reported that
dermoscopy helped them reduce the number of unnecessary
biopsies of benign lesions.
There were high proportions of positive opinions about the








%, n=2413 79.52%, n=2711 <0.001
SD: 10.83) 43.59 (SD: 10.78) <0.001
-
%, n=1921 22.12%, n=759 <0.001
%, n=513 30.22%, n=1037 <0.001
%, n=901 45.85%, n=1573 <0.001
%, n=873 17.40%, n=597 <0.001
%, n=503 12.12%, n=416 1.000
(SD: 10.85) 14.51 (SD: 10.43) <0.001
9 (SD: 369.03) 376.46 (SD: 426.17) <0.001
(SD: 124.79) 16.95 (SD: 48.17) <0.001
%, n=1720 32.37%, n=1092 <0.001
% n=3907 86.18%, n=2957 <0.001
%, n=3950 77.84%, n=2652 <0.001
E






Number of responses 3950 2652










Types of dermoscopes used
–Non-polarized immersion contact 54.15%, n=2139 47.32%, n=1255 <0.001
–Polarized light dermoscope 56.86%, n=2246 41.33%, n=1096 <0.001
–Dermoscope with digital camera 20.20%, n=798 23.87%, n=633 0.005
–Digital video-dermoscopy system 30.38%, n=1200 16.33%, n=433 <0.001













Responders reporting high use of dermoscopy 66.57%, n=2485 56.39%, n=1345 <0.001
























































Increased melanoma recognition due to dermoscopy 83.66%







nd EE (data not shown). Dermatologists in WE reported
lightly higher levels of self-confidence in their dermoscopy
kills for the diagnosis of tumours compared to EE physi-
ians.
rofile of non-users
o pinpoint the main obstacles in dermoscopy use, we com-
ared the characteristics of dermatologists who did not
se dermoscopy between the two sub-regions. (table 3).
he respondents who did not use dermoscopy in WE were
lder, had been practicing dermatology for a longer time,
nd included more males relative to non-users from EE.
he majority (51%) of WE non-users worked in individ-
al private practices, and only 10% in public hospitals. The
pposite was true for non-users in EE (57% of non-users
orking in public hospitals and 14% in private practices).
wenty-seven percent of non-users in WE did not receive
ny form of dermoscopy training, compared to half of non-
sers in EE.
he reasons for not practicing dermoscopy differed signifi-JD, vol. 30, n◦ 5, September-October 2020
antly between the two regions: WE respondents indicated
ost frequently their lack of self-confidence in their der-
oscopic skills (43%), followed by a lack of training
n dermoscopy (33%). Fifteen percent of respondents
bserved that dermoscopy is not useful for their practice
nd 10% considered it too time-consuming. In EE coun-
ries, the main reasons for not using dermoscopy were a








lowed by a lack of training (43%) and lack of confidence
in own skills (21%). Only about 1% of respondents did not
use dermoscopy because it was deemed not useful or too
time-consuming.
Analysis of patterns of dermoscopy use in
relation to country response rates
The country response rate in our survey varied between
6.62% (UK) and 69.5% (Estonia). The response rate corre-
lated inversely with the number of registered dermatologists
(Spearman’s rho = -0.63, p<0.001). Notably, the response
rate by country did not influence the reported rate of der-
moscopy use ( = -0.23, p= 1.00).
Nonetheless, given the large range of response rates, we
conducted a supplementary analysis of the reported der-
moscopy practice by tiers of response rates. Countries were
grouped according to their response rate into three cate-
gories: countries with response rates under 20%, response
rates between 21% and 40%, and response rates of at least
41%. We compared WE vs. EE in each category for selected527
key questions (table 4).
In general, the differences between WE and EE countries
in each category corresponded to the overall analysis of
the two regions. Few exceptions were noted: in the mid-
dle category (response rate: 21-40%), dermoscopy training
during residency was reported by 46% respondents in EE
and 33% WE dermatologists (p<0.001), while in the top
response rate category (≥41%), high use of dermoscopy
5






Number of responses 67 755
Female participants 65.15%, n=43 80%, n=600 0.098
Age (mean) 54.98 (SD: 9.78) 42.71 (SD: 11.62) <0.001
Place of work
-Individual. private practice 50.75%, n=34 14.17%, n=107 <0.001
-Private ambulatory/hospital 10.45%, n=7 26.23%, n=198 0.093
-Public ambulatory/hospital 10.45%, n=7 57.35%, n=433 <0.001
-University/hospital 20.90%, n=14 8.48%, n=64 0.028
-Involved in teaching activity for dermatology residents 20.90%, n=14 7.55%, n=57 0.008
No. of years as dermatology specialist (mean) 23.9 (SD: 10.73) 14.19 (SD: 10.68) <0.001
No. of patients/month (mean) 266.13 (SD: 211.56) 276.75 (SD: 300.48) 1.000
No. of skin cancer patients/month (mean) 41.05 (SD: 108.78) 5.89 (SD: 22.6) 0.150
Dermoscopy training during residency 4.84%, n=3 12.62%, n=94 0.767
No other form of dermoscopy training outside residency 26.87%, n=18 49.93%, n=377 0.008
Reasons for not using dermoscopy
-I do not consider it useful for my practice 14.93%, n=10 1.06%, n=8 <0.001
-The equipment is too expensive 8.96%, n=6 17.75%, n=134 0.767
-A dermoscope is not available in my office 17.91%, n=12 61.19%, n=462 <0.001



























-I am not confident enough in my skills for dermoscopy diagnosis
-It is too time-consuming
-It is not well reimbursed
-Other
as reported more frequently in EE than in WE (62% vs.
6%, p<0.001).
he influence of economic context on
ermoscopy use in Europe
e explored the manner in which the main healthcare-
elated national economic indicators (THEc, GHEc GDPc)
elate to the reported patterns of dermoscopy use. Our
esults for THEc and GHEc overlapped. Similar correlation
oefficients were obtained for GDPc and GHEc, showing a
oderate positive correlation (Spearman rho between 0.5
nd 0.7; p<0.05) with the: rate of dermoscopy use, per-
entage of dermatologists trained for dermoscopy during
esidency, rate of use of non-polarized contact dermoscope,
ate of use of pattern analysis for melanoma diagnosis, and
ercentage of dermatologists who did not use any algorithm
eported in each country. In countries with lower GDPc or
HEc, a lack of a dermoscope in the office, a lack of training
n dermoscopy, and the assessment that dermoscopy equip-
ent was too expensive were the reasons most frequently
aised for not using dermoscopy (Spearman rho between
0.5 to -0.7; p<0.05).28
iscussion
he Eurodermoscopy study, based on the input from 7,500
ermatologists, is the largest of its kind so far and provides
nprecedented insight into the patterns of use, obstacles,
nd facilitators of dermoscopy in the practice of Euro-43.28%, n=29 20.53%, n=155 <0.001
10.45%, n=7 1.19%, n=9 <0.001
4.48%, n=3 4.11%, n=31 1.000
14.93%, n=10 7.02%, n=53 0.328
pean dermatologists. We used this wealth of data to analyse
the differences between countries and regions in the prac-
tice of dermoscopy, on the premise that these differences
might relate to the reported disparities in early detection
and outcome of skin cancers between EE and WE coun-
tries [10, 12, 13, 15, 16], thus these data may serve to
develop context-adapted interventions in order to alleviate
these disparities across the continent.
The large variation in country response rates to our sur-
vey precluded a direct comparison between countries.
Therefore, we performed the analysis at regional level
and compared WE vs. EE regions, which had very close
response rates, ensuring that one in every five registered
dermatologists in each region provided input into our study.
This regional comparison matches the main line of West-
East divergence reported in terms of skin cancer outcomes
and epidemiology [10, 11, 22], but also of cancer care
outcomes, structure of national health systems and socioe-
conomic background [12, 23] across the continent. To
obtain a further, more nuanced, image of the European land-
scape, we conducted the West-East comparison in smaller
groups of countries, defined by comparable response rates.
Our results were largely similar in the overall analysis
(tables 1-3) and within the three subgroups of countriesEJD, vol. 30, n◦ 5, September-October 2020
with similar response rates (table 4). This supports our
findings relative to the variability of survey response rates,
and reinforces the validity of our conclusions regarding
the inter-regional differences in dermoscopy practice and
training.
Noteworthy, the rate of dermoscopy use reported by each
country did not correlate with country survey response
rates. Thus, our study design appears to have precluded











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































selection bias, which is a frequent concern for surveys on
ermoscopy use, as most responders tend to be dermoscopy
sers.
ur survey reported a 20% lower rate of dermoscopy use
n EE compared to WE, combined with a lower rate of
ermoscopy training during or beyond residency and less
eported access to dermoscopy and digital dermoscopy
quipment. The lack of dermoscopy equipment appears to
e the main obstacle in dermoscopy use for most derma-
ologists in EE (61%), while a lack of training appears to
e the main issue in WE. These issues seem to be exac-
rbated in the public healthcare systems, where nearly a
alf of respondents in EE work, including the majority of
ermatologists who do not use dermoscopy. This raises con-
erns regarding the feasibility of wide implementation of
he current best practice guidelines, which recommend the
se of dermoscopy and digital sequential dermoscopy for
he diagnosis and follow-up of skin cancers [6-9].
hile both WE and EE dermatologists agreed that der-
oscopy improves melanoma recognition in their practice,
heir opinions diverge by an estimated 20% regarding the
enefit of dermoscopy in decreasing the number of unnec-
ssary biopsies (table 3). This difference may stem from
nequalities in the level of expertise, in the access to ade-
uate equipment, and in the diagnostic algorithms used.
hus, it has been shown that the rate of unnecessary biopsies
s lowest for dermoscopy experts, in specialised pigment
esion clinics [2, 27, 28], and can be reduced significantly
y short-term monitoring of the patient using sequential
igital dermoscopy (SDD) [4, 29, 30]. However, access to
igital or video dermoscopy devices for SDD was report-
dly available to a minority (12%) of dermatologists in EE
n our study. Over half of EE respondents reported less than
ve years of experience with this technology, while 83% of
E specialists had been using dermoscopy for over five
ears. This confirms that most EE countries adopted this
echnology later, but dermatologists, especially younger
nes, are catching up. Regarding the diagnostic algorithm,
e previously found [19] that the benefits of dermoscopy
n decreasing unnecessary biopsies is reported more fre-
uently by dermatologists using pattern analysis, but less
y those using the ABCD rule. This seems to align with
he present findings that more dermatologists in WE use
attern analysis, while the ABCDE algorithm appears to be
referred by EE dermatologists. These findings feed into
he ongoing debate over the optimal algorithm [1, 31].
inally, the use of dermoscopy is influenced by economic
ackground, which affects all aspects of health care, includ-
ng melanoma survival [12]. We found that the level of
ountry THEc and GDP/capita correlate significantly with
he rate of dermoscopy use as well as with important aspects
f dermoscopy use and training. Since THEc varies between
50 and 7,700 ppp$ (purchasing-power-parity dollars) in
urope [23, 24], this challenge must be acknowledged, and
nnovatively addressed, taking advantage of the opportuni-
ies of digital technology and online knowledge-sharing.30
particular strength of our study are the thousands of
nswers received from dermatologists in EE, as this region
s often under-represented in studies on skin cancer epi-
emiology or health care quality compared to Western
ountries [6, 10, 32, 33] and lacks data on dermoscopy
ractice [34-37]. The Eurodermoscopy project encouraged
articipation of EE countries through its inclusive, context-
dapted survey recruitment methodology, thus achievingunique insight into dermatologists’ practice in all regions
of Europe.
The limitations of the study are related mainly to the
variable response rate, which precluded the direct compar-
ison between individual countries. A breakdown of results
into more sub-regions (e.g. in North, Western, South and
Central-Eastern Europe regions, as used by Globocan and
in related studies [38]) would have reduced the statisti-
cal power of the findings and thus was not performed.
The restriction of the survey to dermatologists and the
reliance on self-reported data on the impact of dermoscopy
on melanoma diagnosis are other limitations of the study
design reported previously [18, 19]. However, the strength
of 7,500 responses, balanced between the two parts of the
continent, provides unique invaluable information.
Conclusion
Dermoscopy is widely used in Europe and helps improve
the diagnosis of early skin tumours, yet its use is signif-
icantly lower in the eastern half of the continent. In this
region, improving access to equipment, especially in public
healthcare facilities, as well as quality training, especially
during residency, appear to be major pathways to enhance
dermoscopy use towards the ultimate goal of reducing the
cross-country inequalities in the early detection of skin
cancers. 
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